Revolution Medicines, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RVMD research report →
About the company
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers.
- CEO
- Mark A. Goldsmith
- IPO
- 2020
- Employees
- 616
- HQ
- Redwood City, CA, US
Price Chart
- Market Cap
- $40.23B
- P/E
- -26.62
- P/S
- 0.00
- P/B
- 24.99
- EV/EBITDA
- -30.50
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -83.22%
- ROIC
- -70.02%
- Revenue
- $0 · 0.00%
- Net Income
- $-1,131,301,000 · -88.52%
- EPS
- $-5.95 · -66.20%
- Op Income
- $-1,182,369,000
- FCF YoY
- -60.94%
- 52W High
- $193.09
- 52W Low
- $34.00
- 50D MA
- $154.51
- 200D MA
- $101.39
- Beta
- 1.41
- Avg Volume
- 3.52M
Get TickerSpark's AI analysis on RVMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 26 | Patel Sushil | other | 2,955 |
| Jun 29, 26 | Patel Sushil | sell | 300 |
| Jun 29, 26 | Patel Sushil | sell | 900 |
| Jun 29, 26 | Patel Sushil | sell | 1,100 |
| Jun 29, 26 | Patel Sushil | sell | 858 |
| Jun 29, 26 | Patel Sushil | sell | 300 |
| Jun 29, 26 | Patel Sushil | sell | 100 |
| Jun 29, 26 | Patel Sushil | sell | 600 |
| Jun 29, 26 | Patel Sushil | sell | 541 |
| Jun 29, 26 | Patel Sushil | sell | 881 |
Our RVMD coverage
Recent articles, reports, and earnings notes.
Want a deeper read on RVMD?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.